Tax Inversion Action? Clock Ticks on Pfizer-Allergan MergerMark Melin
As the Pfizer-Allergan merger talks heat up, shining yet another spotlight on the tax inversion issue, a Goldman Sachs report notes that it is up to the U.S. Treasury and IRS to stem flood of corporations fleeing the U.S. tax system for more friendly climates abroad.
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email firstname.lastname@example.org or click Chat.